Oncology Central

RNA interference in the clinics: where are we standing now?


Over the last decade, the field of cancer therapy and the mode of action of approved cancer drugs have dramatically changed across the globe. The struggle against cancer in clinical trials shifted from the testing of cytotoxic ‘classical’ chemotherapeutic drugs toward agents with clearly defined molecular targets [1].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.